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Gated SPECT Myocardial Perfusion Imaging
for the Prediction of Incident Heart Failure
An Old Dog Learns a New Trick*
Prem Soman, MD, PHD,† James E. Udelson, MD‡
Pittsburgh, Pennsylvania; and Boston, MassachusettsIn the most recent revision of the guidelines for the
evaluation and management of chronic heart failure
(HF) in adults, the American College of Cardiology
and the American Heart Association identified a
pre-clinical stage of HF, stage A, which encom-
passes clinical conditions associated with a high risk
of developing HF (1). Examples of such conditions,
provided in the guideline document, are systemic
hypertension, coronary artery disease (CAD), dia-
betes mellitus, history of cardiotoxic drug therapy or
alcohol abuse, personal history of rheumatic fever,
and family history of cardiomyopathy. This staging
See page 1393
system, including the pre-clinical stage A, stage B
(patients in whom structural heart disease has
developed that is strongly associated with the de-
velopment of HF but who have never shown signs
of symptoms of HF), stage C (patients who have
current or prior symptoms of HF associated with
underlying structural heart disease), and stage D
(advanced HF), reflects the clinical progression of
HF and implies the potential for specific therapies
to be applied to individual stages with the goal of
prevention of progression. The inclusion of a pre-
clinical stage emphasizes the preventive philosophy
in that the identification and treatment of condi-
tions highly likely to progress to overt clinical HF
may impact the natural history of HF favorably. It
is also important to note that once clinical HF
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
From the †Division of Cardiology, University of Pittsburgh Medical
Center, Pittsburgh, Pennsylvania; and the ‡Division of Cardiology, Tufts
Medical Center, Boston, Massachusetts.develops, the prognosis for patients remains worse
than that of many commonly encountered malig-
nancies despite the many therapeutic advances the
field has seen in the past decade (2).
However, conditions included in stage A are
relatively common, and a strikingly large number of
individuals could be included in this stage. For
example, the estimated total number of adults
worldwide with hypertension alone was 957 to 987
million in 2000, and predicted to increase to 1.54 to
1.58 billion in 2025 (3). Thus, strategies to better
identify patients with the greatest risk of developing
clinical HF are necessary to direct the focused
application of preventive strategies.
In this issue of iJACC, Nakata et al. (4) report on
a subanalysis of the J-ACCESS (Japanese Assess-
ment of Cardiac Events and Survival Study by
Quantitative Gated Single-Photon Emission Com-
puted Tomography) database that was designed to
determine the value of myocardial perfusion imag-
ing using single-photon emission computed tomog-
raphy myocardial perfusion scintigraphy (MPS) for
predicting major cardiac events in Japanese patients
with known or suspected CAD. This subanalysis
explored the utility of MPS for predicting the
incidence of overt clinical HF in patients with
known or suspected CAD. This approach is con-
ceptually quite appealing, because MPS is ubiqui-
tously available and widely used for the assessment
of CAD. Furthermore, CAD is currently the most
common underlying etiology of HF (5).
The patients included in the J-ACCESS data-
base were age 20 years or older and referred for
MPS for known or suspected CAD. Patients with
an acute coronary syndrome, valvular or idiopathic
cardiomyopathy, New York Heart Association
functional class III or IV HF, and notably severe
l
f
l
s
r
p
a
p
m
d
m
c
H
s
d
w
t
f
7
O
v
h
fi
c
n
h
b
n
l
t
a
i
g
d
b
r
a
t
p
v
l
u
v
a
t
c
g
v
a
s
M
o
i
r
J
r
t
c
p
p
t
t
t
t
f
w
a
c
r
t
t
i
a
p
s
A
A
w
m
a
p
t
s
p
d
B
p
l
o
p
s
p
d
H
H
p
m
a
c
t
i
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 2 , N O . 1 2 , 2 0 0 9
D E C E M B E R 2 0 0 9 : 1 4 0 1 – 3
Soman and Udelson
Editorial Comment
1402iver or kidney disease were excluded. Also excluded
rom the final analysis were the 223 (4.8%) patients
ost to follow-up, and the 375 (8%) patients cen-
ured for early (60 days after MPS) coronary
evascularization. In addition, 196 patients with
revalent HF at the time of the initial MPS were
lso excluded from the subanalysis, leaving 3,835
atients available for analysis. For the outcome
easure, the authors chose refractory HF, loosely
efined as HF requiring admission and aggressive
edical therapy. As is the common, albeit impre-
ise, practice in HF clinical trials, the diagnosis of
F was established by a combination of clinical
ymptoms and signs and laboratory and imaging
ata. It is important to note that the MPS results
ere unblinded to treating physicians who made
he decision to hospitalize the patient. During the
ollow-up period of 3 years (or until the first event),
1 new-onset (incident) HF admissions occurred.
n univariate analysis, patients in whom HF de-
eloped were older, with a higher prevalence of
ypertension, diabetes mellitus, chronic renal insuf-
ciency, peripheral vascular disease, and prior myo-
ardial infarction (MI) than those in whom HF did
ot develop. Patients in whom HF developed also
ad more myocardial perfusion defects (quantitated
y summed stress scores [SSS]), lower (but not
ecessarily abnormal) ejection fraction, and larger
eft ventricular volumes by gated imaging. Based on
he frequency of the primary outcome, the authors
ppropriately included only the 7 strongest univar-
ate predictors in a Cox proportional hazards re-
ression model. This analysis found chronic renal
ysfunction, end-systolic volume index, and SSS to
e independent predictors of incident HF. Chronic
enal dysfunction was the strongest predictor, with
hazard ratio of 6.22 (95% confidence interval: 2.92
o 13.27). When categorized into tertiles of severity,
atients with a higher SSS and larger end-systolic
olumes had more incident HF.
These findings are not surprising. They are bio-
ogically tenable, and consistent with our current
nderstanding of the interplay between CAD, left
entricular volumes, and incident HF (6). They are
lso consistent with the increasing recognition of
he adverse effect of chronic kidney disease on
ardiovascular outcome (7,8). The novel point of
reat interest in this report relates to the prognostic
alue of combining data on myocardial perfusion
nd function (simultaneously assessed by gated
ingle-photon emission computed tomography
PS) with data on renal function in a large cohort
f subjects. However, before these results can be put bnto clinical perspective, some limitations have to be
ecognized.
First, it is important to note that the original
-ACCESS database recruited patients based on
eferral for diagnostic stress testing. Although pa-
ients with New York Heart Association functional
lass III and IV HF patients were excluded from the
arent study, and this subanalysis further excluded
atients with a prior history of HF, the retrospec-
ive selection of patients for data analysis results in
he inclusion of a population sample whose charac-
eristics are not entirely clear. There is no informa-
ion on the proportion of subjects whose ejection
raction was abnormal at baseline. It is not clear
hether this is a sample of consecutive patients
ssessed at these many centers, or whether the
onsented and enrolled patients represent all of the
eferred patients. These characteristics are impor-
ant to assess the strength of the database as well as
he robustness and generalizability of the results. It
s also noteworthy that many of these patients
lready had structural heart disease in the form of
rior MI, left ventricular chamber enlargement, and
o on, and therefore fall into stage B of the
merican College of Cardiology/American Heart
ssociation classification. Thus, therapy, some of
hich may have preventive effects on the develop-
ent of HF, was already indicated.
Secondly, some important methodological and
nalytical issues were present. Because the treating
hysicians were not blinded to the MPS results,
hey may well have influenced the physicians’ deci-
ions to make the HF diagnosis and hospitalize
atients. It is also not clear how the investigators
ealt with competing risks of death, MI, and HF.
ecause only the first event was used as the end
oint of follow-up, patients who had an MI were no
onger followed up for HF. The confounding effect
f competing risks is one reason why composite end
oints are used in clinical trials.
Finally, the term refractory HF is generally re-
erved for end-stage disease and not for first hos-
italization for HF. What the investigators pre-
icted was the occurrence of incident (new-onset)
F, resulting in hospitalization. This was the only
F end point included among the primary end
oints of the parent study, and the investigators
ost likely did not have data on the development of
ll new-onset HF, which is perhaps the more
linically relevant end point, although challenging
o capture. Hospitalization for HF is certainly
mportant in clinical and economic terms and has
een used as an end point in large clinical trials (9).
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1403Despite these limitations, the context of this
nalysis, that is, the utility of MPS findings along
ith renal function data for the prediction of
ncident HF, with the implicit potential for preven-
ive intervention, is novel and exciting. It provides a
ignal of yet another potential application of MPS,
hich despite being a mature imaging modality,
ontinues to be applied to HF and other cardiac
atients in new and innovative ways (10). Although
he prediction of cardiac death and nonfatal MI in
atients with known or suspected CAD is a well-
stablished strength of MPS, its use for the predic-
ion of new-onset HF has not been extensively
xplored. Although being far from conclusive, the365:217–23. ney disease and theast set the stage for future prospective investiga-
ion in this area. The clinical implications are
mportant for the possibility of focused preventive
trategies. With recent studies exploring its use for
easurement of indexes such as left ventricular
yssynchrony (11) and left ventricular shape indexes
12), the potential applications of MPS continue to
volve. Indeed, the old dog continues to learn new
ricks.
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